Retatrutide vs Semaglutide: 2026 Phase 3 Meta-Analysis

Last updated: May 2026 — incorporates TRIUMPH-1 topline data (released May 21, 2026), TRIUMPH-4 (December 2025), and TRANSCEND-T2D-1 (March 2026).

When we first wrote this comparison in late 2024, retatrutide had only Phase 2 data to its name — a remarkable 24.2% weight loss that outpaced every approved drug on the market. We said Phase 3 would be the real test.

Phase 3 results are now in. And they are not what most observers expected.

They’re better.

This is the first drug in history to deliver bariatric-surgery-level weight loss in a randomized controlled trial without surgery. That sentence deserves to stand on its own before we get into the science.

What Are These Two Drugs?

Before the numbers: a brief primer on why these molecules work the way they do, because the mechanism explains everything that follows.

Semaglutide: The GLP-1 Pioneer

Semaglutide (Ozempic for diabetes, Wegovy for obesity) is a GLP-1 receptor agonist — it mimics glucagon-like peptide 1, a hormone released from the gut after eating. GLP-1 receptors sit in the brain’s hypothalamus and regulate appetite, in the pancreas to control insulin secretion, and in the gut to slow gastric emptying. The result: lower appetite, earlier satiety, better blood sugar control.

Semaglutide was developed by Novo Nordisk and has been in clinical use since 2017. It now has over seven years of post-market safety data across tens of millions of patients. The SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in non-diabetic patients with obesity and established cardiovascular disease — a finding that redefined semaglutide from a weight loss drug to a cardiovascular therapy.

Retatrutide: Triple Agonism

Retatrutide (LY3437943) was developed by Eli Lilly and activates three receptors simultaneously: GLP-1R, GIPR (glucose-dependent insulinotropic polypeptide receptor), and GcgR (glucagon receptor). Each receptor contributes something distinct:

• GLP-1R: Suppresses appetite and slows gastric emptying (same as semaglutide)
• GIPR: Amplifies the GLP-1 effect; may reduce nausea and improve tolerability at higher doses
• GcgR: Increases thermogenesis (energy expenditure) and drives hepatic fat oxidation — the body actively burns more energy, not just eats less

The glucagon receptor component is why retatrutide’s ceiling appears higher than semaglutide’s. Semaglutide primarily reduces energy intake. Retatrutide also increases energy expenditure. These two mechanisms in combination produce weight loss curves that, in Phase 3, have not plateaued even at 80 weeks.

The Phase 3 Weight Loss Data

This is where the 2026 update changes everything. The Phase 2 comparison (24.2% retatrutide vs. 14.9% semaglutide) has been superseded by real Phase 3 evidence.

TRIUMPH-1: The Pivotal Trial (May 2026)

TRIUMPH-1 enrolled 2,339 adults with obesity or overweight plus at least one weight-related comorbidity (but without type 2 diabetes). Treatment duration: 80 weeks. This is the core regulatory anchor trial for the obesity NDA.

Key secondary findings from TRIUMPH-1:

• 45.3% of participants on 12 mg achieved ≥30% body weight loss — a threshold previously associated only with bariatric surgery
• In a prespecified extension of higher-BMI participants (BMI ≥35) to 104 weeks: 30.3% average weight loss
• Weight loss curves had not plateaued at 80 weeks, suggesting the true ceiling is higher still
• Improvements in waist circumference (−24.1 cm at 12 mg), systolic blood pressure, non-HDL cholesterol, triglycerides, and hs-CRP
• All dose levels met the primary endpoint (≥5% weight loss vs placebo) and all key secondary endpoints

Full data will be presented at the 86th ADA Scientific Sessions (2026) and submitted for peer-reviewed publication.

TRIUMPH-4: First Phase 3 Readout (December 2025)

TRIUMPH-4 enrolled 445 adults with obesity or overweight plus knee osteoarthritis — a population of particular interest because excess weight directly worsens joint disease. Duration: 68 weeks.

• Retatrutide 12 mg: 28.7% body weight loss (approximately 71.2 lbs average)
• Retatrutide 9 mg: 26.4%
• Both doses met all primary and key secondary endpoints
• 47–58% of participants achieved ≥25% weight loss; 30–39% achieved ≥30%; 18–24% achieved ≥35%
• Clinically significant reductions in knee osteoarthritis pain scores alongside weight loss

TRANSCEND-T2D-1: Type 2 Diabetes (March 2026)

The first Phase 3 trial in a diabetic population enrolled adults with obesity/overweight and type 2 diabetes. Duration: 40 weeks.

• Retatrutide 12 mg: 16.8% body weight loss (~36.6 lbs average)
• HbA1c reduction: 1.7–2.0% across doses — clinically meaningful glycemic control
• No weight loss plateau observed at 40 weeks

For context: the best approved drug in this population is tirzepatide (Mounjaro), which achieved ~15.7% weight loss with ~2.1% HbA1c reduction in SURPASS-2. Retatrutide’s T2D profile appears comparable to or slightly superior to tirzepatide in this indication.

The Head-to-Head Landscape (Cross-Trial Comparison)

No Phase 3 head-to-head trial has been conducted comparing retatrutide to either semaglutide or tirzepatide. All comparisons below are indirect and should be interpreted as directional, not definitive:

The 80-week TRIUMPH-1 duration is longer than most comparator trials, which matters — weight loss continues accumulating throughout. Even so, the magnitude of difference is striking: retatrutide 12 mg produced roughly 90% more weight loss than semaglutide 2.4 mg (28.3% vs. 14.9%), and approximately 35% more than tirzepatide (28.3% vs. 20.9%).

TRIUMPH Program: Full Trial Status (May 2026)

The TRIUMPH program is Eli Lilly’s Phase 3 obesity program. Here is where each trial stands as of late May 2026:

Side Effect Profiles: Updated With Phase 3 Data

Phase 3 adverse event data from TRIUMPH-1 provides the most clinically meaningful picture to date of retatrutide’s tolerability profile.

Gastrointestinal Effects

Semaglutide 2.4 mg (STEP 1 trial):

• Nausea: 44.2%
• Diarrhea: 31.5%
• Vomiting: 24.5%
• Discontinuation due to GI events: 4.5%

Retatrutide 12 mg (TRIUMPH-1):

• Nausea: 42.4%
• Diarrhea: ~35%
• Vomiting: ~28%
• Discontinuation due to adverse events: 11.3%

The titration nuance: TRIUMPH-1’s titration schedule was aggressive by design (Phase 3 trials often are, to characterize the maximum dose). In clinical practice, the typical 16–24 week titration used with semaglutide and tirzepatide substantially reduces GI adverse events. Lilly’s commercial titration protocol for retatrutide — not yet finalized — will likely be optimized to reduce discontinuation.

Lean Mass and Bone

One area of active scrutiny for all GLP-1-class agents is lean muscle mass loss. Roughly 25–40% of weight lost

Cardiovascular Evidence: A Critical Gap

Semaglutide: SELECT Trial Sets the Standard

The SELECT trial (published NEJM 2023) enrolled 17,604 patients with established cardiovascular disease but without diabetes, randomized to semaglutide 2.4 mg or placebo. Result: 20% relative risk reduction in MACE (cardiovascular death, non-fatal heart attack, non-fatal stroke). The CV benefit appeared to exceed what weight loss alone would explain, implicating direct vascular and anti-inflammatory mechanisms from GLP-1R activation.

This is a landmark finding that elevates semaglutide from a weight management drug to a cardiometabolic therapeutic. For patients with pre-existing cardiovascular disease specifically, semaglutide’s evidence base is unmatched in this class.

Retatrutide: Promising Signals, No Outcomes Data Yet

TRIUMPH-1 cardiometabolic secondary endpoints (announced May 2026) showed meaningful improvements in systolic blood pressure, non-HDL cholesterol, triglycerides, waist circumference (−24.1 cm), and inflammatory marker hs-CRP. These are favorable surrogate markers.

However, retatrutide has no completed cardiovascular outcomes trial.

• TRIUMPH-3 (obesity + established CVD population, safety efficacy trial) — results expected late 2026
• TRIUMPH-CVOT (~18,000 participants, primary MACE endpoint) — enrollment completed Q4 2025; results not expected until approximately mid-2027

Liver Disease (MASH)

Metabolic-associated steatohepatitis (MASH) has become a major battleground for incretin-class agents. The liver angle is where retatrutide’s glucagon receptor component may offer a structural advantage: the glucagon receptor is highly expressed in hepatocytes and glucagon signaling directly drives hepatic fatty acid oxidation and suppresses lipogenesis.

Phase 2 data for retatrutide showed 86% reduction in liver fat at 48 weeks (measured by MRI-PDFF), with 93% of participants achieving normal liver fat levels. These figures exceed Phase 2 data from competing agents.

Phase 3 SYNERGY-MASH ptrial results are expected in 2026, with biopsy-confirmed endpoints that will determine whether the Phase 2 liver signal translates to histological resolution. Semaglutide’s competing ESSENCE trial data for MASH emerged in 2024 and is now guiding regulatory discussions. Both compounds are vying to define a new standard of care for a condition with historically limited treatment options.

Regulatory Status (May 2026)

Semaglutide: Fully Approved

• Ozempic (0.5–2.0 mg/week): FDA approved 2017, Health Canada approved — type 2 diabetes
• Wegovy (2.4 mg/week): FDA approved 2021, Health Canada approved — chronic weight management
• Rybelsus (14 mg/day oral): FDA approved 2019 — type 2 diabetes
• 7+ years of post-market safety data across multiple indications

Retatrutide: Investigational — NDA Expected Q4 2026

• TRIUMPH-1 topline data (May 2026) is the pivotal NDA anchor for obesity without diabetes
• Lilly needs TRIUMPH-2, TRIUMPH-3, and TRANSCEND-T2D data before NDA submission package is complete
• NDA submission: Consensus analyst estimate Q4 2026
• Priority Review (if granted): FDA action ~late 2027
• Standard Review: FDA action ~Q1–Q2 2028
• Current status: Not approved in any jurisdiction. Not available through any legal commercial channel.

Head-to-Head Comparison Table

Frequently Asked Questions

Is retatrutide better than semaglutide for weight loss?

By the single metric of weight loss magnitude, yes — and it’s not close. TRIUMPH-1 Phase 3 data (May 2026) shows retatrutide 12 mg produces 28.3% average weight loss at 80 weeks, compared to semaglutide’s 14.9% at 68 weeks. That’s roughly double. At 104 weeks in higher-BMI patients, retatrutide reached 30.3% — a threshold previously associated only with bariatric surgery. However, “better” overall depends on the clinical question: for patients with established cardiovascular disease who need proven CV risk reduction today, semaglutide’s SELECT trial data is irreplaceable. Retatrutide’s CVOT won’t report until ~2027.

What does the 30% weight loss figure from TRIUMPH-1 mean?

It means, on average, a participant with a starting weight of 250 lbs would lose approximately 75 lbs over two years. This matches the outcomes seen with bariatric surgery — specifically Roux-en-Y gastric bypass (typically 25–35% total body weight loss at 2 years). The implication is that, if Phase 3 data holds through peer review and regulatory scrutiny, retatrutide would represent the first pharmacological treatment to achieve surgical-level weight loss outcomes at scale.

How does retatrutide compare to tirzepatide (Mounjaro/Zepbound)?

Tirzepatide (dual GLP-1/GIP agonist, also from Eli Lilly) achieved 20.9% weight loss in SURMOUNT-1 at 72 weeks. Retatrutide adds the glucagon receptor, which adds approximately 7–8 percentage points of additional weight loss in indirect comparison. The incremental benefit of glucagon receptor activation is the thermogenesis and hepatic fat mobilization pathway — a mechanism that goes beyond appetite suppression alone. There is no head-to-head Phase 3 trial comparing the two.

When will retatrutide be approved?

Based on the TRIUMPH-1 topline readout in May 2026, the prevailing analyst consensus is an NDA submission by Q4 2026. If FDA grants Priority Review, a decision could come as early as late 2027. Standard Review puts approval in Q1–Q2 2028. These are estimates — clinical timelines frequently shift. Health Canada approval would likely follow FDA by 6-12 months.

Is retatrutide available now for research use?

Retatrutide is not approved for any therapeutic use and is not legally available through commercial channels outside of clinical trials. It is an investigational compound only. Any product marketed as “retatrutide” outside an authorized clinical trial is not a regulated pharmaceutical and carries unknown composition and safety risks.

Why does retatrutide cause more weight loss than semaglutide?

Two primary mechanisms. First, the GIP receptor component enhances the GLP-1 effect — the combination of GLP-1R + GIPR produces greater appetite suppression than GLP-1R alone (this is also why tirzepatide outperforms semaglutide). Second, the glucagon receptor activation increases energy expenditure through thermogenesis and drives hepatic fatty acid oxidation. The result is a drug that simultaneously reduces intake and increases output — attacking the energy equation from both sides rather than just one.

Conclusion: The Goalposts Have Moved

The TRIUMPH-1 data released in May 2026 changes the reference point for what obesity pharmacology can achieve. A 28.3% average weight loss in a Phase 3 trial — with no plateau at 80 weeks, and 30.3% in the highest-BMI tsubgroup at 104 weeks — is not an incremental advance. It is a categorical shift.

To put it in historical context: semaglutide was itself a categorical shift when STEP 1 showed 14.9% weight loss in 2021, doubling what any approved drug had achieved to that point. TRIUMPH-1 has now roughly doubled that. The trajectory of this drug class in five years has been extraordinary.

But the comparison between semaglutide and retatrutide is not simply “old vs. new.” It is a comparison between two drugs at different stages of their evidence lifecycle.

Semaglutide has: 7 years of real-world safety data, FDA and Health Canada approval, a proven 20% cardiovascular risk reduction, an established prescribing record, and supply chains that have scaled to serve millions of patients. For a clinician treating a patient with obesity and pre-existing cardiovascular disease today, semaglutide is not merely the approved option — it is the option with demonstrated mortality benefit.

Retatrutide has: The most impressive weight loss data in the history of obesity pharmacology, Phase 3 confirmation of the Phase 2 signal, a mechanistically distinct approach that appears to produce outcomes in a different magnitude class, and a pipeline of CVOT, MASH, and T2D trials that — if positive — would make it the most comprehensive metabolic therapy yet developed. But it has no approval, no MACE outcomes data, limited long-term safety data, and a discontinuation rate that will need to be addressed in prescribing guidelines.

The GLP-1 revolution that semaglutide launched in 2021 didn’t end there. Retatrutide’s Phase 3 data suggests it may have just been the opening act of what metabolic pharmacology can eventually achieve. The remaining question for retatrutide is no longer whether it works — Phase 3 has answered that. The questions now are whether its safety profile is acceptable at scale, whether its cardiovascular benefit will match its metabolic potency, and when patients will actually be able to access it.

Those answers arrive in 2026 and 2027. Watch the ADA 2026 Scientific Sessions presentation of full TRIUMPH-1 data, TRIUMPH-3 results in late 2026, and the official NDA submission announcement from Lilly.

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002.
2. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2. N Engl J Med. 2023;389(6):514–526.
3. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232.
4. Eli Lilly and Company. TRIUMPH-4 Topline Results. Press release, December 11, 2025. investor.lilly.com
5. Eli Lilly and Company. TRIUMPH-1 Topline Results. Press release, May 21, 2026. investor.lilly.com
6. Eli Lilly and Company. TRANSCEND-T2D-1 Topline Results. Press release, March 2026. investor.lilly.com
7. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. (SURMOUNT-1)
8. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844.

This article is for educational and research purposes only. Retatrutide is an investigational compound not approved by Health Canada or the FDA. Nothing in this article constitutes medical advice. Consult a licensed healthcare provider for clinical guidance. Topline trial data cited herein has not yet been peer-reviewed or published in full; findings should be considered preliminary until published.